ERDAFITINIB
- CAS No.
- 1346242-81-6
- Chemical Name:
- ERDAFITINIB
- Synonyms
- JNJ-42756493;CS-2043;Erdafitinib;erdafitnnib;Suftalan Zine;Erdafitinib-d6;2H6]-Erdafitinib;Erdafitinib(JNJ-42756493);JNJ-42756493 (Erdafitinib);5-amino-6-fluoropyridine-7-carbonitrile
- CBNumber:
- CB42725628
- Molecular Formula:
- C25H30N6O2
- Molecular Weight:
- 446.54
- MDL Number:
- MFCD28502040
- MOL File:
- 1346242-81-6.mol
Melting point | 136-140°C |
---|---|
Boiling point | 662.3±55.0 °C(Predicted) |
Density | 1.20±0.1 g/cm3(Predicted) |
storage temp. | -20°C Freezer, Under inert atmosphere |
solubility | DMSO (Slightly), Methanol (Slightly) |
pka | 9.45±0.29(Predicted) |
form | Solid |
color | Yellow |
NCI Dictionary of Cancer Terms | erdafitinib |
FDA UNII | 890E37NHMV |
NCI Drug Dictionary | erdafitinib |
ATC code | L01EX16 |
SAFETY
Risk and Safety Statements
Symbol(GHS) | GHS07,GHS08,GHS05 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Signal word | Danger | |||||||||
Hazard statements | H302-H318-H361-H413-H372-H317 | |||||||||
Precautionary statements | P201-P202-P281-P308+P313-P405-P501-P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P264-P270-P301+P312-P330-P501-P260-P264-P270-P314-P501-P280-P305+P351+P338-P310 | |||||||||
NFPA 704 |
|
ERDAFITINIB price More Price(19)
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
Cayman Chemical | 21813 | JNJ-42756493 ≥98% | 1346242-81-6 | 1mg | $31 | 2024-03-01 | Buy |
Cayman Chemical | 21813 | JNJ-42756493 ≥98% | 1346242-81-6 | 5mg | $85 | 2024-03-01 | Buy |
Cayman Chemical | 21813 | JNJ-42756493 ≥98% | 1346242-81-6 | 10mg | $138 | 2024-03-01 | Buy |
Cayman Chemical | 21813 | JNJ-42756493 ≥98% | 1346242-81-6 | 25mg | $269 | 2024-03-01 | Buy |
TRC | E594600 | Erdafitinib | 1346242-81-6 | 1mg | $45 | 2021-12-16 | Buy |
ERDAFITINIB Chemical Properties,Uses,Production
Description
Erdafitinib is an oral pan-FGFR (1-4) inhibitor with has demonstrated promising activity in patients with metastatic or unresectable UC and other histologies (eg, cholangiocarcinoma) with FGFR alterations. It is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury.
History
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy.
Uses
Erdafitinib is a fibroblast growth factor receptor inhibitor.
brand name
Balversa
General Description
Class: receptor tyrosine kinase; Treatment: metastatic urothelial carcinoma; Other name: JNJ-4275693; Elimination half-life = 59 h; Protein binding = 99.8%
target
Primary targets: Pan-FGFR
ERDAFITINIB Preparation Products And Raw materials
Raw materials
Preparation Products
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
Shanghai Medfine Bio-pharmaceutical Co., Ltd | +8619921460217 | tina.lv@bio-medfine.com | China | 202 | 58 |
ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32715 | 60 |
BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
career henan chemical co | +86-0371-86658258 15093356674; | factory@coreychem.com | China | 29826 | 58 |
Hubei Ipure Biology Co., Ltd | +8613367258412 | ada@ipurechemical.com | China | 10326 | 58 |
HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6313 | 58 |
Finetech Industry Limited | +86-27-87465837 +8618971612321 | info@finetechnology-ind.com | China | 9626 | 58 |
Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10523 | 58 |
Bio Connect Life Sciences | info@bio-connect.nl | United States | 261 | 58 | |
Henan Alfa Chemical Co., Ltd | +8618339805032 | alfa4@alfachem.cn | China | 13039 | 58 |
Related articles
- Erdafitinib can be used to treat urothelial cancer
- Erdafitinib, also known as JNJ-42756493, is a first-in-class pan-fibroblast growth factor receptor (FGFR) kinase inhibitor dis....
- Jan 19,2024
View Lastest Price from ERDAFITINIB manufacturers
Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
---|---|---|---|---|---|---|---|---|
2024-06-07 | Erdafitinib
1346242-81-6
|
US $0.00 / kg | 0.001kg | 99% | kg | Shanghai Medfine Bio-pharmaceutical Co., Ltd | ||
2022-09-27 | Erdafitinib (JNJ-42756493)
1346242-81-6
|
US $0.00-0.00 / kg | 1kg | 98% | 1Ton | Henan Aochuang Chemical Co.,Ltd. | ||
2022-02-18 | ERDAFITINIB
1346242-81-6
|
US $0.00 / gram | 1gram | 99% | 10kg | Zhejiang J&C Biological Technology Co.,Limited |
- Erdafitinib
1346242-81-6
- US $0.00 / kg
- 99%
- Shanghai Medfine Bio-pharmaceutical Co., Ltd
- Erdafitinib (JNJ-42756493)
1346242-81-6
- US $0.00-0.00 / kg
- 98%
- Henan Aochuang Chemical Co.,Ltd.
- ERDAFITINIB
1346242-81-6
- US $0.00 / gram
- 99%
- Zhejiang J&C Biological Technology Co.,Limited